Introduction
============

Radiotherapy represents a cornerstone of the treatment of breast cancer. In the past, the less advanced technology was the cause of severe damage to surrounding tissues in the breast, lung and chest wall. Today the planning of irradiation fields guarantees the near total absence of collateral effects, in particular pneumonia and fibrosis induced by radiotherapy \[[@B1]\].

Radiation-induced pneumonia occurs classically 4 to 12 weeks after the radiotherapy and is characterized by fever, dry cough, dyspnea and alveolar opacities confined to the treatment port \[[@B2]\]. However, bilateral lymphocytic alveolitis develops in both lungs after strictly unilateral breast irradiation and it presents with the histological, radiological and clinical pattern of bronchiolitis obliterans organizing pneumonia (BOOP), now currently defined as cryptogenic organizing pneumonia (COP) \[[@B3]\].

COP is a distinct clinico-pathological entity in the wide family of pulmonary fibrosis, and is characterized by patchy and often migratory peripheral air space infiltrates on chest radiography \[[@B4],[@B5]\]. COP has been associated with radiotherapy for breast cancer in some case reports, and it has been defined as \"radiation-primed COP\" \[[@B6]\].

Corticosteroid treatment in COP results in rapid clinical improvement of clinical symptoms and clearing of the opacities on chest imaging without sequelae. Although the efficiency of steroids in COP has long been established, the precise dose, the duration of treatment, the use of boluses and the withdrawal have not been defined in radiation-primed COP \[[@B7],[@B8]\].

We report a case of COP after radiotherapy for breast cancer, presenting with fever, dyspnea, respiratory failure and bilateral pneumonia. The disease was successfully treated with systemic steroids but relapsed after the steroid withdrawal, and was definitively resolved after a second steroid course. This case emphasizes the importance of taking into account the possible occurrence of radiation-primed COP, and clarifies why only few women become affected with this disease after radiotherapy, what the optimal dose and duration of treatment should be, and if (and, if so, which) respiratory function tests can predict this complication.

Case Report
===========

A 62-year-old woman was admitted to our out-patient clinic with a 2-week history of fever, dyspnea and dry cough. Her chest radiography revealed pneumonia in the left lower lobe, already treated with antibiotics without benefit. She had undergone left mastectomy 1 year earlier, and subsequent adjuvant radiation treatment after the surgery for 50 days. In addition, immediately after the surgical procedure she had been given therapy with anastrozole (Arimidex^©^), that was still in course at the onset of symptoms. Computerized tomography (CT) scan showed a pulmonary infiltration with ground glass opacities in the left lower lobe outside the irradiation fields, diagnosed as pneumonia (Figure [1](#F1){ref-type="fig"}). Biochemical analysis revealed no abnormalities, except for elevated levels of C-reactive protein (CRP) (18 mg/dl), and the arterial blood gas analysis showed a mild hypoxemia (PaO~2~68 mm Hg, PaCO~2~31 mm Hg, pH 7.43, FiO~2~21%).

![**Computerized tomography (ct) scan at first occurrence of symptoms**.](2049-6958-5-6-432-1){#F1}

The initial treatment was based on antibiotics for the clinical diagnosis of pneumonia, but clinical symptoms of dry cough and dyspnea persisted. Given the ineffectiveness of prolonged antibiotic therapy, a fiberoptic bronchoscopy was performed with bronchoalveolar lavage (BAL) and trans-bronchial biopsy (TBBx). The BAL fluid revealed a mild lymphocytic alveolitis (total cell count: 840/μL; lymphocytes: 15%; macrophages 84%; neutrophils 1%; CD4+/CD8+ T-lymphocyte ratio: 1.1). TBBx was not diagnostic, and no malignant cells or pathogenic bacteria were discovered in the BAL fluid. Pulmonary function tests showed a mild restrictive defect with reduction of CO-transfer: forced vital capacity (FVC) 82% of predicted value (pred.), forced expiratory volume in 1 sec (FEV~1~) 78% pred., lung diffusion capacity for carbon monoxide (DL~CO~) 67% pred., KCO 82% pred.

Based on clinical, radiographic and laboratory data, radiation-primed COP was diagnosed and a treatment with systemic steroids was started at the dose of 1 mg/kg of body weight with tapering to half dose every 4 weeks (total duration of treatment 22 weeks). The CT scan, pulmonary function tests, blood gas analysis and CRP at 12 weeks after the start of steroids were all normalized.

Four weeks after steroid withdrawal, the patient began to complain again of dry cough and dyspnea. A new CT scan revealed newly formed opacities in the upper right and in the middle lobes (Figure [2](#F2){ref-type="fig"}). The patient underwent an identical treatment with systemic steroids, that resulted in an immediate improvement of symptoms, that persisted after 6 and 12 months. A complete normalization of CT images, pulmonary function tests (FVC 94% pred., FEV~1~90% pred., DL~CO~84% pred., KCO 92% pred.), CRP value (0.5 mg/dl) and blood gas analysis (PaO2 72 mm Hg, PaCO~2~39 mm Hg, pH 7.40, FiO~2~21%) was present at 12 months of follow up.

![**Second ct scan at the relapse of disease**.](2049-6958-5-6-432-2){#F2}

Discussion
==========

Reports of COP related to radiotherapy in breast cancer, in the form of case reports or literature analysis \[[@B9],[@B10]\], date back to 15 years ago. COP is very similar to radiation pneumonia, but it involves lung segments that are far from the radiation field. Patients who undergo radiation therapy to the breast may present alveolar lymphocytosis, even if they do not develop pneumonia. The negative effects of radiotherapy are well documented in the literature (Table [1](#T1){ref-type="table"}), but the histological and clinical pattern of radiation-primed COP in the lung seems to depict a distinct entity, with the epidemiological data, diagnostic and therapeutic algorithm not well defined yet. The prevalence of radiation-primed COP ranges between 2.5% and 1.8% \[[@B11]-[@B13]\], but, to our knowledge, there are no Italian or more local data available, that could be very useful to clarify the influence of differences in radiation method, dosing, and collimation on the occurrence of this pulmonary complication.

###### 

Synopsis of the literature on collateral effects of radiotherapy

  Lung            Pneumonia                  1-3 months (acute) 12-15 months (late)   30 Gy                                                 Mosvas et al.      Chest 1997;111:1061
  --------------- -------------------------- ---------------------------------------- ----------------------------------------------------- ------------------ ------------------------------------------
  Breast          COP                        6 wk to 10 months                        no minimal dose defined                               Crestani et al.    ERJ 1995;8:318
                                                                                                                                                               
  Lymph nodes     Calcifications             12 months                                no minimal dose defined                               Bereton et al.     Radiology 1974;112:705
                                                                                                                                                               
  Esophagus       Stricture                  3-18 months                              60 Gy                                                 Lepke et al.       Radiology 1993;148:375
                                                                                                                                                               
  Vascular tree   Stenosis or occlusion      10-15 years                              Aorta and pulm. artery 24-44 Gy Subclavian 40-60 Gy   Fajardo et al.     Pathol Ann 1988;23:297
                                                                                                                                                               
  Heart           Coronary artery disease    10-15 years                              \> 30 Gy age \< 20                                    Kopelson et al.    Int J Radiat Oncol Biol Phys 1978;4:895
                  Pericarditis               12-48 months                             40 Gy                                                 Applefeld et al.   Ann Intern Med1981;94:338
                  Conduction abnormalities   10 years                                 40 Gy                                                 Cohen et al.       Arch Intern Med1981;141:676
                                                                                                                                                               
  Chest wall      Sarcoma                    \> 5 years                               no minimal dose defined                               Libshitz           Semin Roent 1994;29:15
                  Rib fractures              \> 12 years                              50 Gy                                                 Pierce et al.      Int J Radiat Oncol Biol Phys 1992;23:915
                  Breast carcinoma           15-19 years                              \> 20 Gy age \< 35                                    Bhatia et al.      NEJM 1996;334:745

The primary role of pleural factors has been described in one sole report \[[@B9]\] but not confirmed in an analysis of the recent literature \[[@B8]\]. Currently, an immunological mechanism is thought to be at the base of the disease development, as in hypersensitivity pneumonitis: irradiation provokes a tissue damage with sensitization of autoreactive lymphocytes, which react with pulmonary tissues \[[@B14]\]. However, it is also possible that lymphocytes are not the key cells in the pathogenesis of radiation primed COP; mast-cells could play a role, as in idiopathic COP and hypersensitivity pneumonia caused by inhaled antigens \[[@B15]\]. In addition, some studies \[[@B16]\] have shown that radiotherapy induces gene activation and transcription, cytokine release and fibroblasts activation. The cause of the migratory pattern and involvement of lung tissue away from the radiation fields remains unclear.

Therefore, the role of diagnostic methods like bronchoscopy with BAL appears essential and well defined to identify the alveolar pattern of lung involvement. Not equally defined is the role of TBBx, because a specific histological pattern has never been reported. From a clinical point of view, we limited the invasive procedures to TBBx due to the first result of absence of malignant cells or specific bacterial results, and the fast response to treatment.

Considering how many women undergo surgery and radiotherapy for breast cancer, radiation-primed COP is not so common, and probably different individual elements and/or factors related to the dose and length of radiation therapy are implicated in the occurrence and progression of this pulmonary complication.

A general review of the literature by Cordier \[[@B8]\] shows that the modifications of pulmonary function tests are generally mild or moderate, frequently consisting in a restrictive defect, even if an obstructive pattern can be present in patients with smoking habit or affected by chronic obstructive pulmonary disease. However, since the second half of the 1980s no report has clarified the changes of lung volume, blood gas analysis or CO-transfer factor during COP, nor the possible risk patterns of lung damage detectable before the breast surgery and radiotherapy.

Katayama et al. \[[@B17]\] showed a relation between radiation-primed COP and hormone therapy with tamoxifen, anastrozole and toremifen, reporting a significant association (OR 3.12, 95% CI 1.12-8.68, p = 0.03). Our patient received anastrozole, but it was interrupted at the first occurrence of respiratory symptoms. However, it is rather difficult to precisely determine the influence of the withdrawal of this drug on the occurrence of the pulmonary complication, and alternatively on the outcome of the breast cancer.

It seems really important to know which drugs represent a real risk factor for this complication, when they are able to exert a significant role and why this disease occurs in only few patients, with a reported greater incidence in subjects aged more than 50 years \[[@B17]\].

In radiation-primed COP, as in other unknown diseases, therapy with systemic steroids is effective even if relapses are described after withdrawal \[[@B6]\]. The doses of systemic steroids range from 0.5 to 1 mg/kg of body weight a day, but due to the serious unwanted effects of these drugs, like diabetes and osteoporosis, especially in elderly women, the literature is not updated about the lowest effective dose that can be used and the timing of dose tapering.

This case report shows a postmenopausal woman submitted to surgery and radiotherapy and successively to hormone-therapy for breast cancer. The patient presented symptoms of fever, dry cough and dyspnea 4 months after radiotherapy; radiological signs resembled pneumonia; BAL was suggestive of lymphocytic alveolitis; all therapies were ineffective, but systemic steroids induced the complete resolution of lung opacities and symptoms. This case, by and large, is similar to previous case reports.

However, to date, radiation primed COP still remains unclear, with unknown causes, risk factors, role and timing of non invasive diagnostic tests, e.g. pulmonary function tests, and of invasive tests such as bronchoscopy with BAL and TBBx, except for the possibility of excluding a diagnosis of cancer or tuberculosis.

Thus, we think it would be very useful to obtain epidemiological data about all women undergoing surgery and radiotherapy for breast cancer, to reveal possible relationships between radiation, hormonetherapy, and individual factors, in particular concerning the respiratory function before and during the treatment.
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